Skip to Main Content

New Mammography Quality Measures Available for Beta Testing

Feb. 8, 2024

The Centers for Medicare and Medicaid Services (CMS) Measures Management System posted a public comment period, open through Feb. 26, for four new breast cancer-related measures developed by Acumen, LLC. These include three quality measures and one episode-based cost measure intended to assess clinician performance in breast cancer screening and diagnosis and improve patient outcomes. An informational webinar about the measures will be held Feb. 13, 3–4pm ET.

The codes are:

  • Breast Cancer Screening Recall Rate Quality Measure (Outcome).
  • Breast Cancer Screening with an Eventual Breast Cancer Diagnosis: Positive Predictive Value 1 (PPV1) Quality Measure (Outcome).
  • Use of Biopsy After Diagnostic Follow-up with an Eventual Breast Cancer Diagnosis: Positive Predictive Value 3 (PPV3) Quality Measure (Outcome).
  • Breast Cancer Screening Episode-Based Cost Measure.

The testing process is an important step in determining whether these measures could eventually be adopted into CMS’ Merit-based Incentive Payment System. Feedback can be provided via the 2024 Beta Testing Feedback Survey through 11:59pm ET, Feb. 26.

If you have questions, contact Samantha Shugarman, American College of Radiology® Director of Quality Programs.


Related ACR News

  • President Biden Issues Executive Order to Advance Women's Health Research and Innovation

    The White House released an Executive Order (EO) to Advance Women’s Health Research and Innovation March 18, as part of the Biden Administration’s White House Initiative on Women’s Health Research. The EO directs a multitude of federal agencies to develop and strengthen research and data standards on women’s health across all relevant research and funding opportunities. These actions build on the recent announcement of the Advanced Research Projects Agency for Health Sprint for Women’s Health, which committed $100 million toward transformative research and development in women’s health.

    Read more

  • Partner With ACR in ARPA-H $100 Million Funding Opportunity to Improve Women's Health Outcomes

    The Advanced Research Projects Agency for Health (ARPA-H) recently announced the Sprint for Women’s Health, a funding opportunity for researchers to discover unconventional approaches and innovative ways to push high-impact biomedical research forward to improve women’s health outcomes. ARPA-H intends the effort to fundamentally change the trajectory of women’s healthcare research and radically accelerate the next generation of discoveries. A total of $100 million is available through the effort.

    Read more

  • FDA Document Outlines MQSA Final Rule Requirements

    The U.S. Food and Drug Administration (FDA) posted a new information document to assist mammography facilities subject to the Mammography Quality Standards Act (MQSA) final rule. Amended MQSA regulations take effect Sept. 10.

    Read more